Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors
BACKGROUND: A comprehensive review and description of the clinical features that impact prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is needed. Understanding survival and prognostic features is paramount for clinical advancements and patient care. METHODS: PubMed,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466272/ https://www.ncbi.nlm.nih.gov/pubmed/36105387 http://dx.doi.org/10.1093/noajnl/vdac133 |
_version_ | 1784787958598991872 |
---|---|
author | Crowell, Cameron Mata-Mbemba, Daddy Bennett, Julie Matheson, Kara Mackley, Michael Perreault, Sébastien Erker, Craig |
author_facet | Crowell, Cameron Mata-Mbemba, Daddy Bennett, Julie Matheson, Kara Mackley, Michael Perreault, Sébastien Erker, Craig |
author_sort | Crowell, Cameron |
collection | PubMed |
description | BACKGROUND: A comprehensive review and description of the clinical features that impact prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is needed. Understanding survival and prognostic features is paramount for clinical advancements and patient care. METHODS: PubMed, Embase, and Google Scholar were searched for English articles published between January 1, 2012 and June 30, 2021. Eligible studies included patient(s) of any age diagnosed with an H3 G34-mutant brain tumor with at least one measure of survival or progression. Patient-level data were pooled for analyses. This study was prospectively registered in PROSPERO (CRD42021267764) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. RESULTS: Twenty-seven studies met the criteria with a total of 135 patients included. Median age at diagnosis was 15.8 years (interquartile range [IQR]: 13.3–22.0) with 90% having localized disease. Co-occurring alterations included ATRX mutation in 93%, TP53 mutation in 88%, and MGMT promoter methylation in 70%. Median time-to-progression was 10.0 months (IQR: 6.0–18.0) and median overall survival was 17.3 months (95% CI: 15.0 to 22.9). The median time from progression to death was 5.0 months (IQR: 3.0–11.7). Factors associated with survival duration were age, as patients ≥18 y/o demonstrated longer survival (hazard ratio [HR] =2.05, 95% CI: 1.16 to 3.62), and degree of upfront resection, as near or gross-total resection demonstrated longer survival compared to those with less than near-total resection (HR = 3.75, 95% CI: 2.11 to 6.62). CONCLUSION: This systematic review highlights available clinical data for G34-DHG demonstrating poor outcomes and important prognostic features, while serving as a baseline for future research and clinical trials. |
format | Online Article Text |
id | pubmed-9466272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-94662722022-09-13 Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors Crowell, Cameron Mata-Mbemba, Daddy Bennett, Julie Matheson, Kara Mackley, Michael Perreault, Sébastien Erker, Craig Neurooncol Adv Meta-Analysis BACKGROUND: A comprehensive review and description of the clinical features that impact prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is needed. Understanding survival and prognostic features is paramount for clinical advancements and patient care. METHODS: PubMed, Embase, and Google Scholar were searched for English articles published between January 1, 2012 and June 30, 2021. Eligible studies included patient(s) of any age diagnosed with an H3 G34-mutant brain tumor with at least one measure of survival or progression. Patient-level data were pooled for analyses. This study was prospectively registered in PROSPERO (CRD42021267764) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. RESULTS: Twenty-seven studies met the criteria with a total of 135 patients included. Median age at diagnosis was 15.8 years (interquartile range [IQR]: 13.3–22.0) with 90% having localized disease. Co-occurring alterations included ATRX mutation in 93%, TP53 mutation in 88%, and MGMT promoter methylation in 70%. Median time-to-progression was 10.0 months (IQR: 6.0–18.0) and median overall survival was 17.3 months (95% CI: 15.0 to 22.9). The median time from progression to death was 5.0 months (IQR: 3.0–11.7). Factors associated with survival duration were age, as patients ≥18 y/o demonstrated longer survival (hazard ratio [HR] =2.05, 95% CI: 1.16 to 3.62), and degree of upfront resection, as near or gross-total resection demonstrated longer survival compared to those with less than near-total resection (HR = 3.75, 95% CI: 2.11 to 6.62). CONCLUSION: This systematic review highlights available clinical data for G34-DHG demonstrating poor outcomes and important prognostic features, while serving as a baseline for future research and clinical trials. Oxford University Press 2022-08-19 /pmc/articles/PMC9466272/ /pubmed/36105387 http://dx.doi.org/10.1093/noajnl/vdac133 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Meta-Analysis Crowell, Cameron Mata-Mbemba, Daddy Bennett, Julie Matheson, Kara Mackley, Michael Perreault, Sébastien Erker, Craig Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors |
title | Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors |
title_full | Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors |
title_fullStr | Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors |
title_full_unstemmed | Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors |
title_short | Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors |
title_sort | systematic review of diffuse hemispheric glioma, h3 g34-mutant: outcomes and associated clinical factors |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466272/ https://www.ncbi.nlm.nih.gov/pubmed/36105387 http://dx.doi.org/10.1093/noajnl/vdac133 |
work_keys_str_mv | AT crowellcameron systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors AT matambembadaddy systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors AT bennettjulie systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors AT mathesonkara systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors AT mackleymichael systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors AT perreaultsebastien systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors AT erkercraig systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors |